New data show Gilenya® (fingolimod) reduced brain volume loss by one third and confirm link between brain volume loss and MS disability

Brain volume loss is emerging as a significant indicator of disability progression over the long-term in MS, and is a topic of much interest within the MS medical community.³ Loss of brain volume has been observed to occur at higher rates in patients with MS than in the general population. The average rate of brain volume loss in a person without MS over one year is 0.1% to 0.3%.

Increasingly, research focus is on treatments that will reduce the rate of brain volume loss. Fingolimod is the only NICE recommended oral treatment for RRMS that has shown early and consistent slowing of brain volume loss,5-8 and the new data presented at ECTRIMS add to the growing evidence base for fingolimod's efficacy and reinforce the correlation between brain volume loss and disability progression over the long-term.